(Q36706397)

15 August 2017

Ketanserin in essential hypertension: a double-blind, placebo-controlled study (English)

1 reference

15 August 2017

0 references

essential hypertension

1 reference

Cameron HA

1

1 reference

15 August 2017

Ramsay LE

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 July 1985

1 reference

Postgraduate Medical Journal

15 August 2017

1 reference

15 August 2017

61

1 reference

15 August 2017

717

1 reference

15 August 2017

583-586

1 reference

Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2418322

Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2418322

Mechanism of antihypertensive action of ketanserin in man

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2418322

Haemodynamics in Essential Hypertension

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2418322

Vascular smooth muscle. II. Pharmacology of normal and hypotensive vessels

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2418322

The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2418322

Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2418322

Sample size for short-term trials of antihypertensive drugs

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2418322

The antihypertensive effects of ketanserin (R 41468), a novel 5-hydroxytryptamine-blocking agent, in patients with essential hypertension

5 September 2018

1 reference

12 December 2020

The variable arterial pressure response to serotonin in laboratory animals and man

1 reference

12 December 2020

Mechanism of antihypertensive action of ketanserin in man

1 reference

12 December 2020

Pharmacokinetics of ketanserin in man

1 reference

12 December 2020

Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist

1 reference

12 December 2020

The effect of ketanserin in essential hypertension

1 reference

12 December 2020

Identifiers

DOI

10.1136/PGMJ.61.717.583

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

3161013

1 reference